TrialsgrambetaRCTs are beautiful

PRAGUE-17

2020

Left Atrial Appendage Closure versus Novel Anticoagulation Agents in Atrial Fibrillation

In 402 high-risk patients with non-valvular atrial fibrillation, percutaneous left atrial appendage closure was non-inferior for a composite of cardiovascular and bleeding events compared with direct oral anticoagulants.

Result

Efficacy: Composite of stroke, TIA, systemic embolism, CV death, major/CRNM bleeding, or procedure/device complicationssubdistribution HR 0.84 (95% CI 0.53-1.31) · P = 0.004

Below 1 favours percutaneous left atrial appendage closure, above 1 favours direct oral anticoagulants.

Event rates
Absolute difference
2.43 points

The absolute difference is derived from the event rates.

Also reported: LAA closure non-inferior to DOACs.

Original publication
Subtopic
LAAO
Design
Multicentre open-label non-inferiority RCT
Relevance
Supporting: context rather than must-know.
Source
Osmancik P, et al. J Am Coll Cardiol. 2020;75(25):3122-3135.doi 10.1016/j.jacc.2020.04.067

Discussion & critique

Modest size and few events limit precision, and findings apply to high-bleeding-risk patients. First RCT to show LAA occlusion non-inferior to DOACs, extending device evidence beyond the warfarin era.

Discussed in podcasts